Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation

View Full Paper
Ask AI
Bookmark
Share

Authors

LRLindsey RikeSHS. R. HintonCHCorinne Hoffman

Discussion

Loading...

Member takes

Overview

Phase II study shows improved safety and efficacy of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation, indicating potential for better outcomes.

Key Points

  • Combination therapy shows enhanced outcomes in richter transformation, highlighting its effectiveness.
  • Median progression free survival reported at 31.4 months in previous studies, indicating strong response rates.
  • Phase II study aims to measure objective response rate and safety using 2014 Lugano criteria for evaluation.
  • Results may highlight the role of tumor microenvironment and adverse events related to treatment combinations.

Cite This Study

Rike et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d655https://doi.org/10.1182/blood-2025-1953
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Correlates of response to combined checkpoint and BTK inhibition for treatment of richter transformation: Extended follow-up from the prospective RT1 trial2025
  2. 2Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma2025
  3. 3Trial in progress: Treatment of CNS lymphoma with zanubrutinib and tislelizumab: A phase ib/II investigator-initiated study2025
  4. 4Pirtobrutinib, venetoclax, and obinutuzumab for patients with richter transformation: A phase 2 trial2025
  5. 5Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025